Equine LN antibody and antigen (recombinant protein)
Diagnostic anti-Equine LN antibodies pairs and antigen for animal health (animal Equine/Horse muscular dystrophy, lethal skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome) testing in ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA and POCT
Go to Equine disease testing products collection >>
Product information
Catalog No. | Description | US $ Price (per mg) |
---|---|---|
GMP-EQU-LN-Ag01 | Equine LN | $3090.00 |
GMP-EQU-LN-Ab01 | Anti-Equine LN mouse monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-LN-Ab02 | Anti-Equine LN mouse monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-LN-Ab03 | Anti-Equine LN human monoclonal antibody (mAb) | $3090.00 |
GMP-EQU-LN-Ab04 | Anti-Equine LN human monoclonal antibody (mAb) | $3090.00 |
Size: 1mg | 10mg | 100mg
Product Description
Cat No. | GMP-EQU-LN-Ag01 |
Product Name | Equine LN |
Target/Biomarker | Equine LN |
Expression platform | E.coli |
Isotypes | Recombinant Antigen |
Bioactivity validation | Anti-Equine LN antibodies binding, Immunogen in Sandwich Elisa, lateral-flow tests, and other immunoassays as control material in LN level test of animal Equine/Horse with muscular dystrophy, lethal skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome. |
Tag | His | Reconized/Reactive Specics | Equine LN |
Product description | Recombinant Equine LN protein was expressed in E.coli - based prokaryotic cell expression system and is expressed with 6 HIS tag at the C-terminus. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-EQU-LN-Ab01,GMP-EQU-LN-Ab02 |
Target/Biomarker | Equine LN |
Product Name | Anti-Equine LN mouse monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Mouse IgG |
Bioactivity validation | Recombinant Equine LN antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine LN antibodies in Equine LN level test of animal Equine/Horse with muscular dystrophy, lethal skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome. |
Product description | Anti-Equine LN mouse monoclonal antibody (mAb) is a mouse monoclonal antibody produced by CHO technology. The antibody is ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine LN antibodies. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Cat No. | GMP-EQU-LN-Ab03,GMP-EQU-LN-Ab04 |
Target/Biomarker | Equine LN |
Product Name | Anti-Equine LN human monoclonal antibody (mAb) |
Expression platform | CHO |
Isotypes | Human lgG1 |
Bioactivity validation | Recombinant Equine LN antigen binding, ELISA validated as capture antibody and detection antibody. Pair recommendation with other anti-Equine LN antibodies in Equine LN level test of animal Equine/Horse with muscular dystrophy, lethal skin blistering disease (junctional epidermolysis bullosa) and nephrotic syndrome. |
Product description | Anti-Equine LN mouse monoclonal antibody (mAb) is a human monoclonal antibody produced by CHO. The antibody is ELISA validated as capture antibody and detection antibody pair. |
Purity | Purity: ≥95% (SDS-PAGE) |
Application | Paired antibody immunoassay validation in Sandwich ELISA, ELISA, colloidal gold-based Lateral flow immunoassay (LFIA), CLIA, TINIA, POCT and other immunoassays. |
Formulation | Lyophilized from sterile PBS, PH 7.4 |
Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Validation Data
Click to get more Data / Case study about the product.
Target/Biomarker Information
The Equine Lymph Node (eLN) stands as a sentinel in the complex network of equine immunity, an unsung hero safeguarding a horse's health. Positioned strategically in various anatomical regions, the eLN tirelessly monitors the horse's interstitial fluid, capturing antigens, and orchestrating immune defenses with precision and expertise.
Structurally, the eLN is an encapsulated organ, enclosed by a fibrous tissue known as the capsule. This capsule houses a labyrinth of lymphatic sinuses and nodules where immune cells reside and interact. Within these microenvironments, immune cells are stationed, primed to detect and respond to potential threats. Among these immune cells, lymphocytes, the primary players of adaptive immunity, abound. T cells and B cells, distinct lymphocyte subsets, collaborate to recognize and target specific antigens, while macrophages act as the body's professional scavengers, clearing cellular debris and engulfing foreign invaders.
When antigens enter the lymphatic fluid, either through infection or other means, a series of events unfolds within the eLN. Antigen-presenting cells, including dendritic cells, encounter these antigens and capture them. They then migrate to the eLN, where they present the antigens to T cells. This presentation serves as a call to arms, activating T cells that recognize the specific antigen. B cells within the eLN also play a crucial role by producing antibodies that can neutralize invaders.
The eLN, in essence, functions as a training ground for immune cells. It is where naïve lymphocytes are exposed to antigens, learn to differentiate self from non-self, and develop memory responses. This training is critical for the horse's ability to mount swift and specific immune defenses upon subsequent encounters with the same antigens.
About GDU
GDU helps global diagnostic partners in high quality of raw material discovery, development, and application. GDU believes in Protein&antibody Innovation for more reliable diagnostic solutions.